相关实验视频

Updated: Jan 17, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

彻底改变威尔逊病的预后:一种机器学习方法来预测急性-慢性肝衰竭

Zhihong Rao¹, Wenming Yang^2,3,4, Yulong Yang¹

¹Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, 117 Meishan Road, Hefei, 230031, Anhui, China.

Journal of translational medicine

|September 24, 2025

概括

这项研究开发了一种机器学习模型,用于预测威尔逊病 (WD) 患者急性至慢性肝衰竭 (ACLF) 风险. 该XGBoost模型准确地识别了使用TBA和APTT等生物标志物进行早期干预的高风险个体.

科学领域:

肝病学肝病学是一种肝病学.
医疗信息学医疗信息学
生物化学生物化学

背景情况:

威尔逊病 (WD) 是一种铜代谢的遗传性疾病.
WD可以导致急性至慢性肝衰竭 (ACLF),这是一个危及生命的疾病,进展迅速.

研究的目的:

开发和验证基于机器学习 (ML) 的模型,用于预测WD患者的ACLF风险.
确定与WD中ACLF发展相关的关键临床和生化标志物.

主要方法:

对3692名WD患者的回顾性分析 (莱比锡得分≥4).
使用六个ML算法 (LR,SVM,KNN,ExtraTrees,XGBoost,LightGBM) 开发预测模型.
使用SHAP进行特征重要性分析,以确定关键预测因素.

主要成果:

XGBoost模型表现出卓越的性能,AUC为0.998,准确度为0.968.
ACLF风险的关键预测因素包括TBA,APTT,诊断年龄,发病年龄和Hb.
增加的TBA,APTT和诊断年龄与增加的ACLF风险有关,而较低的发病年龄和Hb表明结果较差.

结论:

一个基于ML的模型,特别是XGBoost,可以有效地预测WD-ACLF风险.
TBA,APTT,诊断年龄,发病年龄和Hb是风险分层的关键生物标志物.
该模型为患有ACLF风险的WD患者的早期临床干预提供了可操作的见解.

关键词:

急性-慢性肝功能衰竭肝功能衰竭肝功能衰竭机器学习是机器学习.这就是 SHAP SHAP 的意思.威尔逊病是威尔逊病的一种疾病.在XGBoost中使用.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...